Edwards Lifesciences (EW) has drawn fresh attention after unveiling extensive clinical data at the New York Valves 2026 conference. The company highlighted results from the PROGRESS, EARLY TAVR and PARTNER 3 trials on its SAPIEN platform.

Alongside the New York Valves data, Edwards Lifesciences has attracted fresh attention from its index reclassification, with recent additions to several Russell value and defensive indices coinciding with a 13.36% 90 day share price return and a 16.07% 1 year total shareholder return. However, longer term total shareholder returns remain slightly negative over three and five years, suggesting momentum has picked up only more recently.

If this kind of clinical and index driven move has you thinking about what else might be setting up for a rerating, it could be worth scanning 40 healthcare AI stocks for more potential opportunities across the broader healthcare technology space.

With Edwards Lifesciences up 13.36% over 90 days and 16.07% over the past year, yet still showing slightly negative 3 and 5 year total returns, is this a fresh entry point, or is the market already pricing in future growth?

Most Popular Narrative: 6.3% Undervalued

Edwards Lifesciences closed at $90.78 against a widely followed fair value narrative of $96.92, putting the focus firmly on what is driving that gap.

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Want to see what sits underneath that fair value for Edwards Lifesciences? Revenue compounding, margin reset, and a future earnings multiple that assumes real execution. The exact mix of growth, profitability and discount rate assumptions might surprise you.

Result: Fair Value of $96.92 (UNDERVALUED)

However, Edwards Lifesciences still faces tariff related cost pressure and potential earnings dilution from the JenaValve acquisition, which could challenge the current fair value narrative.

Another View: Edwards Lifesciences Through Market Multiples

While the fair value narrative for Edwards Lifesciences points to a modest 6.3% gap to $96.92, the current P/E of 48.6x tells a tougher story. That multiple is well above the US Medical Equipment industry at 26.2x, peers at 25x, and a fair ratio of 29.1x, which leaves far less room for error if earnings or margins disappoint.

For investors weighing these signals, the question is whether the recent clinical and policy momentum justifies paying such a premium, or if the P/E could drift closer to the fair ratio and peer levels over time.

Next Steps

With sentiment split between opportunity and caution around Edwards Lifesciences, it makes sense to move quickly, review the underlying data, and decide where you stand. To balance the upside potential with the risks that investors are watching, take a moment to weigh the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Edwards Lifesciences?

If the Edwards Lifesciences story has sharpened your focus, do not stop there. The right screener can surface other opportunities you will not want to miss.

• Spot potential mispricings early by scanning 44 high quality undervalued stocks that may currently trade below what their fundamentals suggest.
• Strengthen your defense by checking 69 resilient stocks with low risk scores designed for investors who want resilience front and center.
• Get ahead of the crowd by filtering through a screener containing 19 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.